TY - JOUR
T1 - Nanotherapeutics for treatment of pulmonary arterial hypertension
AU - Segura-Ibarra, Victor
AU - Wu, Suhong
AU - Hassan, Nida
AU - Moran-Guerrero, Jose A.
AU - Ferrari, Mauro
AU - Guha, Ashrith
AU - Karmouty-Quintana, Harry
AU - Blanco, Elvin
N1 - Funding Information:
We thank Matthew G. Landry for assistance with schematics. This work was supported by the George and Angelina Kostas Research Center for Cardiovascular Nanomedicine. VS-I is grateful for support from the Instituto Tecnológico y de Estudios Superiores de Monterrey and the Consejo Nacional de Ciencia y Tecnología (CONACyT, 490202/278979). MF is grateful for the Ernest Cockrell Jr. Presidential Distinguished Endowed Chair in the Department of Nanomedicine at the Houston Methodist Research Institute. AG is grateful for funding from the Vaughan Foundation. HK-Q is grateful for funding from the National Institutes of Health (NIH 1R01 HL138510-01) and the UTHealth Pulmonary Center of Excellence Discovery Award Program.
Publisher Copyright:
© 2018 Segura-Ibarra, Wu, Hassan, Moran-Guerrero, Ferrari, Guha, Karmouty-Quintana and Blanco.
PY - 2018/7/13
Y1 - 2018/7/13
N2 - Pulmonary arterial hypertension (PAH) is a devastating and fatal chronic lung disease. While current pharmacotherapies have improved patient quality of life, PAH drugs suffer from limitations in the form of short-term pharmacokinetics, instability, and poor organ specificity. Traditionally, nanotechnology-based delivery strategies have proven advantageous at increasing both circulation lifetimes of chemotherapeutics and accumulation in tumors due to enhanced permeability through fenestrated vasculature. Importantly, increased nanoparticle (NP) accumulation in diseased tissues has been observed pre-clinically in pathologies characterized by endothelial dysfunction and remodeled vasculature, including myocardial infarction and heart failure. Recently, this phenomenon has also been observed in preclinical models of PAH, leading to the exploration of NP-based drug delivery as a therapeutic modality in PAH. Herein, we discussed the advantages of NPs for efficacious treatment of PAH, including heightened therapeutic delivery to diseased lungs for increased drug bioavailability, as well as highlighted innovative nanotherapeutic approaches for PAH.
AB - Pulmonary arterial hypertension (PAH) is a devastating and fatal chronic lung disease. While current pharmacotherapies have improved patient quality of life, PAH drugs suffer from limitations in the form of short-term pharmacokinetics, instability, and poor organ specificity. Traditionally, nanotechnology-based delivery strategies have proven advantageous at increasing both circulation lifetimes of chemotherapeutics and accumulation in tumors due to enhanced permeability through fenestrated vasculature. Importantly, increased nanoparticle (NP) accumulation in diseased tissues has been observed pre-clinically in pathologies characterized by endothelial dysfunction and remodeled vasculature, including myocardial infarction and heart failure. Recently, this phenomenon has also been observed in preclinical models of PAH, leading to the exploration of NP-based drug delivery as a therapeutic modality in PAH. Herein, we discussed the advantages of NPs for efficacious treatment of PAH, including heightened therapeutic delivery to diseased lungs for increased drug bioavailability, as well as highlighted innovative nanotherapeutic approaches for PAH.
KW - Chronic lung disease
KW - Drug delivery
KW - Nanomedicine
KW - Nanoparticles
KW - Pulmonary arterial hypertension
UR - http://www.scopus.com/inward/record.url?scp=85049859652&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049859652&partnerID=8YFLogxK
U2 - 10.3389/fphys.2018.00890
DO - 10.3389/fphys.2018.00890
M3 - Review article
AN - SCOPUS:85049859652
SN - 1664-042X
VL - 9
SP - 890
JO - Frontiers in Physiology
JF - Frontiers in Physiology
IS - JUL
M1 - 890
ER -